Abstract
The number of COVID-19 deaths is often used as a key indicator of SARS-CoV-2 epidemic size. 42 However, heterogeneous burdens in nursing homes and variable reporting of deaths in elderly 43 individuals can hamper comparisons of deaths and the number of infections associated with them 44 across countries. Using age-specific death data from 45 countries, we find that relative differences 45 in the number of deaths by age amongst individuals aged <65 years old are highly consistent across 46 locations. Combining these data with data from 15 seroprevalence surveys we demonstrate how 47 age-specific infection fatality ratios (IFRs) can be used to reconstruct infected population 48 proportions. We find notable heterogeneity in overall IFR estimates as suggested by individual 49 serological studies and observe that for most European countries the reported number of deaths 50 amongst ≥65s are significantly greater than expected, consistent with high infection attack rates 51 experienced by nursing home populations in Europe. Age-specific COVID-19 death data in 52 younger individuals can provide a robust indicator of population immunity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge funding from the University of Cambridge COVID-19 Rapid Response Grant, the Investissement d'Avenir program, the Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases program (grant ANR-10-LABX-62-IBEID), Sante Publique France, the INCEPTION project (PIA/ANR-16-CONV-0005), and the European Union's Horizon 2020 research and innovation program under grants 101003589 (RECOVER) and 874735 (VEO), AXA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All code and data necessary to reproduce this analysis are available at 491 https://github.com/meganodris/International-COVID-IFR .
